Read by QxMD icon Read

Expert Opinion on Drug Delivery

Estela R García, Stefanie Thalhauser, Hèctor R Loscertales, Pilar Modamio, Cecilia F Lastra, Eduardo L Mariño
As the elderly population and polypharmacy are increasing, it is predicted that interventions to enhance medication adherence, as dose administration aids (DAA), will grow. One of the limitations of repackaging medicines into DAA is to assure the stability of medicines, and, therefore, their quality, efficacy and safety. Area covered: This article collects and summarises data of all the stability studies of repackaged medicines into DAAs. Computerized search in databases: PubMed, Google Scholar, SciELO, and reference texts related to the field (keywords: drug stability, DAAs, compliance aids, and repackaging), open access databases and guidelines...
May 31, 2018: Expert Opinion on Drug Delivery
Stanley Cohen, Piotr A Klimiuk, Tillmann Krahnke, Deepak Assudani
BACKGROUND: This study examined the patient handling experience and self-injection success of patients with rheumatoid arthritis (RA) administering BI 695501 using an AI. METHODS: This Phase II, 7-week, open-label, interventional study (NCT02636907) included adult patients with moderately to severely active RA not adequately controlled by DMARDs, with no experience of self-injecting with AI/pen. Patients self-injected BI 695501 via AI every 2 weeks in the AI Assessment Period (AAP)...
May 15, 2018: Expert Opinion on Drug Delivery
Joseph V Pergolizzi, Robert Taylor, Jo Ann LeQuang, Robert B Raffa
There is no greater public health threat at this time in America than the opioid abuse crisis, and a systematic, level-headed, coherent, and unified approach is needed. Among the many things that have been proposed to help reduce opioid abuse is the development of opioid analgesic products in abuse-deterrent formulations (ADFs). This seems to make perfect sense. Areas Covered: In this article, the viewpoints of 12 stakeholders (physicians, pain patients, payers, manufacturers, regulators, law enforcement, hospitals, first responders, elected officials, rehabilitation centers, opioid addicts, and the general public) were considered in terms of how ADF opioids are regarded and might contribute potential impediments to more widespread use...
May 9, 2018: Expert Opinion on Drug Delivery
Jing Yu, Sachin Dubey, Yogeshvar N Kalia
BACKGROUND: Dermatological diseases, including most skin cancers and rare genetic conditions frequently originate in the epidermis. Targeted, topical cell-based therapy is a promising therapeutic strategy. Here, we present the first report demonstrating that fractional laser ablation enables local "needle-free" intraepidermal delivery of living human cells. METHODS: The cells penetrated porcine ear skin via microchannels created by Er:YAG fractional laser ablation; cell delivery was quantified using a haemocytometer...
May 8, 2018: Expert Opinion on Drug Delivery
Mukta Agrawal, Swarnlata Saraf, Shailendra Saraf, Sophia G Antimisiaris, Nobuhito Hamano, Shyh-Dar Li, Mahavir Chougule, Sunday A Shoyele, Umesh Gupta, Ajazuddin, Amit Alexander
Brain is supposed to be the most complicated part of the body which is very far from the reach of drug moieties. The drug entry in to the brain region depends upon various factors, and among those, the blood-brain-barrier remains the most prominent one. This barrier restricts the entry of almost all the drug and most of the essential biological components like proteins, peptides, etc. and hinders treatment of the CNS disorders. Alzheimer Disease (AD) is one such brain disorder, more specifically a neurodegenerative disorder which primarily affects the older adults...
May 7, 2018: Expert Opinion on Drug Delivery
Helen Saunders, Laura de la Fuente Bitaine, Chriss Eftekhar, Colin M Howles, Johanna Glaser, Tina Hoja, Pablo Arriagada
OBJECTIVE: The main objective of this user experience testing study was to evaluate the impact of human factors on the use of a disposable pen containing follitropin alfa by patients and nurses with special focus on the convenience, safety and ease of use, in different types of stimulation protocols. METHODS: Infertile women trying to conceive, and specialist nurses were recruited across 6 European countries. In total 18 patients and 19 nurses took part in the testing, which included both nurse-patient pairings and in-depth interviews...
April 6, 2018: Expert Opinion on Drug Delivery
Kevin Craig, Marc Abrams, Mansoor Amiji
Oligonucleotide therapeutics have the potential to change the way disease is treated due to their ability to modulate gene expression of any therapeutic target in a highly specific and potent manner. Unfortunately, this drug class is plagued with inherently poor pharmacological characteristics, which need to be overcome. The development of a chemical modification library for oligonucleotides has addressed many of the initial challenges, but delivery of these payloads across plasma membranes remains difficult...
June 2018: Expert Opinion on Drug Delivery
Sven Stegemann
The advances in drug delivery technologies have enabled pharmaceutical scientists to deliver a drug through various administration routes and optimize the drug release and absorption. The wide range of drug delivery systems and dosage forms represent a toolbox of technology for the development of pharmaceutical drug products but might also be a source of medication errors and nonadherence. Patient centric drug product development is being suggested as an important factor to increase therapeutic outcomes. Areas covered: Patients have impaired health and potentially disabilities and they are not medical or pharmaceutical experts but are requested to manage complex therapeutic regimens...
June 2018: Expert Opinion on Drug Delivery
Jeong Woo Lee, Mark R Prausnitz
No abstract text is available yet for this article.
June 2018: Expert Opinion on Drug Delivery
E Millart, S Lesieur, V Faivre
The development of multifunctional drug carriers provides many opportunities in the field of drug delivery. Among them, carriers loaded with both drug and superparamagnetic iron oxide nanoparticles would allow the combination of chemotherapy with the possibility of monitoring or controlling the distribution of the nanocarrier in the body, triggering drug release and/or applying a synergistic hyperthermia treatment. Areas covered: The present review covers biocompatible lipid-based nanotechnologies that have been employed to co-encapsulate drug and iron oxide...
May 2018: Expert Opinion on Drug Delivery
Ziyu Zhao, Zhengwei Huang, Xuejuan Zhang, Ying Huang, Yingtong Cui, Cheng Ma, Guanlin Wang, Tim Freeman, Xiang-Yun Lu, Xin Pan, Chuanbin Wu
BACKGROUND: The hygroscopicity of raffinose carrier for dry powder inhaler (DPI) was the main obstacle for its further application. Hygroscopicity-induced agglomeration would cause deterioration of aerosolization performance of raffinose, undermining the delivery efficiency. METHODS: Cyclodextrin-raffinose binary carriers (CRBCs) were produced by spray-drying so as to surmount the above issue. Physicochemical attributes and formation mechanism of CRBCs were explored in detail...
May 2018: Expert Opinion on Drug Delivery
Lorenzo Vannozzi, Veronica Iacovacci, Arianna Menciassi, Leonardo Ricotti
Traditional drug release systems normally rely on a passive delivery of therapeutic compounds, which can be partially programmed, prior to injection or implantation, through variations in the material composition. With this strategy, the drug release kinetics cannot be remotely modified and thus adapted to changing therapeutic needs. To overcome this issue, drug delivery systems able to respond to external stimuli are highly desirable, as they allow a high level of temporal and spatial control over drug release kinetics, in an operator-dependent fashion...
May 2018: Expert Opinion on Drug Delivery
Joan Schertz, Hilary Worton
BACKGROUND: Owing to the wide-ranging role nurses have in supporting patients undergoing fertility treatment, we recorded the learning/teaching expectations and experiences of nurses using a redesigned fertility pen injector. METHODS: This was a multicentre, simulated-use study, using unbranded placebo-filled pens. Before teaching patients, nurses were given free choice to rank the importance of the device attributes and predict the level of patient anxiety. Nurses taught 2-5 patients how to prepare the device, inject the dose and complete an incomplete dose...
May 2018: Expert Opinion on Drug Delivery
Gunjan Vasant Bonde, Sarita Kumari Yadav, Sheetal Chauhan, Pooja Mittal, Gufran Ajmal, Sathish Thokala, Brahmeshwar Mishra
Breast cancer stands the second prominent cause of death among women. For its efficient treatment, Lapatinib (LAPA) was developed as a selective tyrosine kinase inhibitor of receptors, overexpressed by breast cancer cells. Various explored delivery strategies for LAPA indicated its controlled release with enhanced aqueous solubility, improved bioavailability, decreased plasma protein binding, reduced dose and toxicity to the other organs with maximized clinical efficacy, compared to its marketed tablet formulation...
May 2018: Expert Opinion on Drug Delivery
Yuqi Zhang, Jicheng Yu, Di Wen, Guojun Chen, Zhen Gu
No abstract text is available yet for this article.
May 2018: Expert Opinion on Drug Delivery
João Pedro Martins, Giulia Torrieri, Hélder A Santos
Nanoparticles are anticipated to overcome persistent challenges in efficient drug delivery, but the limitations associated with conventional methods of preparation are resulting in slow translation from research to clinical applications. Due to their enormous potential, microfluidic technologies have emerged as an advanced approach for the development of drug delivery systems with well-defined physicochemical characteristics and in a reproducible manner. Areas covered: This review provides an overview of microfluidic devices and materials used for their manufacturing, together with the flow patterns and regimes commonly used for nanoparticle preparation...
May 2018: Expert Opinion on Drug Delivery
Antonella Obinu, Elisabetta Gavini, Giovanna Rassu, Marcello Maestri, Maria Cristina Bonferoni, Paolo Giunchedi
Lymphatic vessels are the preferential route of most solid tumors to spread their metastases in the body. The onset of metastatic nests in draining lymph nodes (LNs) are a significant indicator of cancer progression and a dismaying sign of worsen staging. Therefore, the individuation and elimination of cancer cells within the lymphatic system (LS) are an important goal. Nevertheless, the targeting of the LS with traditional contrast agents and/or chemotherapeutics is difficult, due to its anatomical structure...
May 2018: Expert Opinion on Drug Delivery
Smrithi Padmakumar, Neha Parayath, Fraser Leslie, Shantikumar V Nair, Deepthy Menon, Mansoor M Amiji
Epithelial ovarian cancer (EOC) remains to be the most lethal of all gynecological malignancies mainly due to its asymptomatic nature. The late stages are manifested with predominant metastases confined to the peritoneal cavity. Although there has been a substantial progress in the treatment avenue with different therapeutic interventions, the overall survival rate of patients remain poor due to relapse and drug resistance. Areas covered: The pharmacokinetic advantages offered by intraperitoneal (IP) chemotherapy due to peritoneal-plasma barrier can be potentially exploited for EOC relapse treatment...
May 2018: Expert Opinion on Drug Delivery
M Peppi, A Marie, C Belline, J T Borenstein
No abstract text is available yet for this article.
April 2018: Expert Opinion on Drug Delivery
Zahraa S Al-Ahmady
The development of therapeutics for central nervous system (CNS) disorders is still considered a challenging area in drug development due to insufficient translocation through the blood-brain barrier (BBB). Under normal conditions, BBB restrict the penetration of more than 98% of blood-borne molecules including drugs to the CNS. However, recent research findings have proven that the nature of the BBB is altered in several neurological conditions. This complexity encourages revisiting drug delivery strategies to the CNS as this can give a wide range of opportunities for CNS drug development...
April 2018: Expert Opinion on Drug Delivery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"